Sartorius Q1 Strength

Sartorius opened 2026 with faster sales growth and steady margins, adding to signs that biopharma customers are buying more routine production supplies again. (sartorius.com) The Göttingen, Germany-based life sciences group said first-quarter sales reached €899 million, up 7.5% in constant currencies from a year earlier, while underlying earnings before interest, taxes, depreciation and amortization margin held at 29.7%. (sartorius.com) Its Bioprocess Solutions division, which sells equipment and disposable supplies used to make biologic drugs, grew 8.1% in constant currencies. Lab Products & Services, which serves research and quality-control labs, rose 4.9%. (webdisclosure.com) Bioprocessing consumables are the filters, bags and other single-use parts that drugmakers reorder every production run. Sartorius said the quarter’s growth was driven by that recurring business, while bioprocess equipment improved only slightly and lab instruments remained restrained. (sartorius.com) That mix echoes 2025, when Sartorius said growth came mainly from higher-margin consumables as customers stayed cautious on bigger equipment purchases. The company reported full-year 2025 sales of €3.54 billion and an underlying EBITDA margin of 29.7%. (sartorius.com) Chief Executive Michael Grosse said April 23 that “demand for consumables in both divisions is recovering,” and that equipment and instruments should improve over the rest of 2026. Sartorius kept its full-year forecast for group sales growth of about 6% to 7% in constant currencies and an underlying EBITDA margin of about 29% to 30%. (webdisclosure.com) At its listed bioprocess subsidiary, Sartorius Stedim Biotech, first-quarter sales were €762 million, up 7.9% in constant currencies, with an underlying EBITDA margin of 30.7%. The company said that business was also led by consumables for biopharma manufacturing. (sartorius.com) Sartorius has been leaning harder into biopharma after outlining updated strategy and mid-term targets at its March 2026 capital markets day. The company said then it would sharpen its focus on biopharma customers and target sustained above-market growth. (webdisclosure.com) For now, the first quarter points to a recovery led by repeat-use supplies rather than a broad rebound in large instruments. Sartorius’ guidance still assumes the rest of 2026 brings more improvement than the opening three months. (sartorius.com)